Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INM005 in Adult Patients With Moderate to Severe COVID-19
NCT04494984Phase 3Completed
- Sponsor
- Inmunova
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, scFv Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of equine immunoglobulin anti SARS-CoV-2 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Inmunova. Primary endpoint: Improvement in at Least Two Categories in WHO 8-point Ordinal Clinical Scale at Day 28. Started Jul 2020; status: completed.
02
Drugs
equine immunoglobulin anti SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04494984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494984.